{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T06:11:04Z","timestamp":1745993464696},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ijrobp.2015.10.019","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T12:21:41Z","timestamp":1445775701000},"page":"289-296","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck"],"prefix":"10.1016","volume":"94","author":[{"given":"Ricard","family":"Mes\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Garc\u00eda-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Carles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Irigoyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Ma\u00f1\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Garc\u00eda-Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"del Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miren","family":"Taberna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.10.019_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data","volume":"355","author":"Pignon","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib3","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib4","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib5","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta-analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib6","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermoken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2006.08.8005","article-title":"Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab","volume":"25","author":"Curran","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib11","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2009.22.1333","article-title":"Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"27","author":"Haddad","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib12","first-page":"1311","article-title":"Feasibility of cetuximab plus sequential platinum-based therapy (TPF\/CRT) in advanced squamous cell head and neck cancer (SCCHN): A randomized phase II study of the EORTC Head and Neck Cancer Group","volume":"269","author":"Vermorken","year":"2012","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib13","series-title":"American Joint Committee on Cancer: Cancer Staging Manual","first-page":"217","author":"Greene","year":"2002"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib15","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.oraloncology.2012.06.014","article-title":"Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: A meta-analysis","volume":"11","author":"Ma","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.27741","article-title":"A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck","volume":"119","author":"Adkins","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib17","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","article-title":"Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer","volume":"28","author":"Argiris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2009.23.0425","article-title":"Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial","volume":"28","author":"Kies","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib19","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/annonc\/mdu248","article-title":"Induction cetuximab, paclitaxel and carboplatin followed by chemoradiation with cetuximab, paclitaxel and carboplatin for stage III\/IV head and neck squamous cancer: A phase II ECOG-ACRIN trial (E2303)","volume":"25","author":"Wanebo","year":"2014","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.ijrobp.2015.10.019_bib20","volume":"29","author":"Seiwert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib21","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib22","unstructured":"Taberna M, Hierro C, V\u00e1zquez S, et\u00a0al. Late toxicity after radical treatment for locally advanced head-and-neck carcinomas. Poster presented at: Multidisciplinary Head and Neck Cancer Symposium. February 20-22, 2014; Scottsdale, AZ."},{"key":"10.1016\/j.ijrobp.2015.10.019_bib23","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.1994.12.8.1592","article-title":"Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group","volume":"12","author":"Spaulding","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.019_bib24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/01.mlg.0000231736.08477.47","article-title":"Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma","volume":"116","author":"Majem","year":"2006","journal-title":"Laryngoscope"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615265844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615265844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T19:43:39Z","timestamp":1556567019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615265844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0360301615265844"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.019","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}